TY  - JOUR
AU  - Valldeoriola, F
AU  - Grandas, F
AU  - Arbelo, J M
AU  - Blázquez Estrada, M
AU  - Calopa Garriga, M
AU  - Campos-Arillo, V M
AU  - Garcia Ruiz, P J
AU  - Gómez Esteban, J C
AU  - Leiva Santana, C
AU  - Martínez Castrillo, J C
AU  - Mir, P
AU  - Salvador Aliaga, A
AU  - Vivancos Matellano, F
AU  - Yáñez Baña, R M
PY  - 2020
DO  - 10.1016/j.nrleng.2018.04.004
UR  - https://hdl.handle.net/10668/24373
T2  - Neurologia
AB  - Safinamide is a new add-on drug to levodopa for the treatment of Parkinson's disease (PD) with motor fluctuations. Due to the recent incorporation of safinamide into routine clinical practice, no post-authorisation phase IV studies on the safety of...
LA  - en
KW  - Discinesias
KW  - Dyskinesia
KW  - Fluctuaciones
KW  - Fluctuations
KW  - Glutamate
KW  - Glutamato
KW  - Inhibidores de la MAO
KW  - MAO-B inhibitors
KW  - Parkinson
KW  - Safinamida
KW  - Safinamide
KW  - Alanine
KW  - Antiparkinson Agents
KW  - Benzylamines
KW  - Consensus
KW  - Humans
KW  - Parkinson Disease
KW  - Spain
TI  - Spanish expert consensus on the use of safinamide in Parkinson's disease.
TY  - research article
VL  - 36
ER  -